Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis (Bio-CHIC)

This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).

b-cell lymphoma
burkitt's lymphoma
large cell lymphoma
chemoimmunotherapy
da-epoch
  • 42 views
  • 31 Jan, 2022
  • 16 locations
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

allo-HSCT. Patients from group C are treated either according to the "Aza-Ida-Ara-C" scheme, or according to the "Ven-DAC /AZA" scheme, followed by mandatory allo-HSCT.

  • 0 views
  • 28 Apr, 2022
  • 1 location
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy

  • 0 views
  • 27 Jan, 2021
  • 19 locations
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

This study proposes to provide adequate treatment and is based on current scientific evidence for elderly patients with ALL Bcr / Abl positive. To determine whether low-dose chemotherapy associated with imatinib or dasatinib has acceptable tolerability in elderly patients. To determine whether this association can increase the rate and quality …

  • 1 views
  • 28 Jun, 2022
  • 1 location
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 (BMTCTN1903)

This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma

  • 0 views
  • 22 Mar, 2022
  • 5 locations
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

20-25% of patients over 15 years with acute lymphoblastic leukemia (ALL) have the Philadelphia chromosome or BCR-ABL rearrangement. Traditionally, intensive chemotherapy followed by hematopoietic stem cell transplantation (HSCT) have formed the basis allogeneic treatment of this disease, but the results have been poor (60-75% complete remissions-RC-and probability of long-term survival …

  • 103 views
  • 26 Mar, 2022
  • 73 locations
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.

r-chop
neutrophil count
chop regimen
melphalan
vincristine
  • 120 views
  • 23 Feb, 2022
  • 51 locations
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients 60 Years Old

biology (secondary AML, therapy related AML). Patients with a low risk of relapse will be allocated to consolidation, with three courses of high doses of Ara-C (HiDAC), or two courses of HiDAC with

ara-c
decitabine
acute promyelocytic leukemia
myelodysplastic syndromes
cytarabine/daunorubicin
  • 32 views
  • 07 Oct, 2021
  • 10 locations
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

chemotherapy. To compare two consolidation regimens: high dose cytarabine (HD Ara-C) and fludarabine & cytarabine (FLA) in standard risk patients. To compare the toxicity and

gilbert's syndrome
gemtuzumab
ejection fraction
flow cytometry
blast cells
  • 0 views
  • 26 Jan, 2022
  • 69 locations
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

In this multicenter, upfront randomized phase II trial, all patients receive quizartinib in combination with HAM (high-dose cytarabine, mitoxantrone) during salvage therapy. Efficacy is assessed by comparison to historical controls based on the matched threshold crossing approach. During consolidation therapy (chemotherapy as well as allo-HCT) patients receive either prophylactic quizartinib …

  • 0 views
  • 28 Jan, 2021
  • 1 location